What Is
CanceRx Doing
We are offering short-duration investment to create a dedicated clinical testing organization. Short and medium duration investments will be used to start up enterprise operations, ramp up licensing and fund the CanceRx CRO, a wholly owned contract research organization (CRO). All clinical research projects will be funded separately by bond issuance.
The CanceRx financing model is underpinned by work from Dr. Andrew Lo and the Nobel Laureate faculty at MIT’s Laboratory for Financial Engineering. This approach uses bonds to fund long-term and multiple products in clinical development. This strategy statistically lowers risk and improves the investment attractiveness of drug candidates, filling a key gap in the commercialization pipeline.
Accredited investors are invited to sign up for access to a prospectus.
Register here to be granted access to a prospectus. Approved registrations will be notified via their submitted email address with login instructions. To discuss investment opportunities, contact Cody Gibbons, COO.
Register
By submitting this form, you are consenting to receive marketing emails from: CanceRx. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact